



Nuance Pharma Closes Series D Financing

Funds will support ongoing research & development and further business development

SHANGHAI, China, [December 07], 2020 (PR Newswire) – Nuance Pharma, a biopharmaceutical company engaged in creating value through China’s specialty pharmaceutical markets with an established focus on iron deficiency, pain management and respiratory, today announced that it has successfully closed its Series D financing which amounted to US\$181 million of funding.

The Series D financing is led by RTW Investments, LP, and GT Fund with additional support from existing investors including CBC Group, Matrix Partners China and HBM Healthcare Investments, and new investors including Konruns Pharmaceutical (603590.SH), etc.

Proceeds from the financing will be used in the ongoing research and development of Nuance’s existing products and business development of potential new assets. To date, the Company has made important progress with its broad pipeline and seeks to further strengthen its presence in these key therapeutic areas.

“This is an important milestone for Nuance Pharma, which reinforces our deep industry expertise and strategic business model.” said Mark Lotter, founder and CEO of Nuance. “We are well-positioned to advance the clinical development of our robust therapeutics pipeline, and we look forward to bringing in more assets to China and building a leading presence in these key therapeutic areas”.

About Nuance

Nuance is a fully integrated pharmaceutical company engaged in creating value through China’s specialty pharmaceutical markets, with an established focus on iron deficiency, pain management and respiratory. Nuance is founded in 2014 and has received multiple rounds of financing from leading investors which include the CBC Group (formerly C-Bridge Capital), one of the largest and most active healthcare-dedicated investment firms in Asia, and Matrix Partners China.

About CBC Group

CBC Group (formerly C-Bridge Capital) is one of the largest and most active healthcare-dedicated investment firms in Asia focused on platform-building and buyout opportunities across three core areas within the healthcare sector: pharmaceutical & biotech, medtech and healthcare services. CBC’s operationally intensive approach empowers healthcare sector champions to make transformative changes to enable sustainable long-term growth, fulfill unmet medical needs and continuously improve the standard of living and quality of care in China and the rest of Asia. Founded in 2014, CBC has a strong team of investment, healthcare and portfolio management professionals based across Singapore, Shanghai, Beijing, Hong Kong and New York.

About RTW Investments, LP

RTW Investments, LP (“RTW”) is a New York-based, global, full life-cycle investment firm that focuses on identifying transformational and disruptive innovations in biopharmaceutical and medical technologies. As a leading partner of industry and academia, RTW combines deep scientific expertise with a solution-oriented investment approach to support emerging medical therapies and the companies and/or academics developing them.

About GT Fund

Zhejiang Manufacturing Fund LLP as part of Guoxin Guotong Fund LLP (collectively “GT Fund”) is a private equity fund incorporated in Hangzhou, China, in 2017 with total size of CNY 10 billion (c.US\$1.4 billion). It has the mandate to provide capital and professional support to industrial partners in the region. GT Fund specializes in cross-border investment projects following the principles of market-orientation, professionalism and internationalization and is actively investing in the field of healthcare, advanced manufacturing, clean energy, etc. GT Fund's portfolio of investments seeks to provide superior risk-adjusted returns to its co-investors as well as limited partners. Guoxin Guotong Fund LLP is a private equity fund established in 2016 with total size of CNY 150 billion (c.US\$21.1 billion).



优锐医药完成 D 轮融资

资金将支持正在进行的产品研发以及下一阶段的业务发展

中国，上海，[12月07日]，2020年（美通社）——优锐医药，一家致力于中国特殊护理药物市场的制药公司，重点关注缺铁性贫血、术后疼痛管理和呼吸系统疾病三大领域，今天宣布成功完成了1.81亿美元D轮融资。

本次D轮融资由国新国同（GT Fund）和RTW Investments, LP（RTW）领投。该轮融资也获得了康桥资本（CBC Group）、经纬中国（Matrix Partners China）和HBM Healthcare Investments等现有投资者和康辰药业（603590.SH）等新投资者的支持。

融资所得将用于优锐医药现有产品的持续研发以及潜在新产品的商业发展。目前，优锐医药已经通过其丰富的产品管线取得了重要进展，并将进一步加强其在关键治疗领域的药物研发地位。

“这是优锐医药重要的里程碑，强化了我们深厚的行业专业知识和战略商业模式。”优锐医药的创始人兼首席执行官 Mark Lotter 表示。“我们已经准备好推进我们强大的产品管线的临床研发，并期待向中国引入更多产品，在这些关键的治疗领域建立领先地位。”

关于优锐医药

优锐医药是一家致力于中国特殊护理药物市场的制药公司，重点关注缺铁性贫血、术后疼痛管理和呼吸系统疾病三大领域。优锐医药成立于2014年，过去数年获得了包括康桥资本（亚洲最大、最活跃的医疗行业投资机构之一）和经纬中国在内的顶尖投资者的多轮融资。

关于康桥资本 CBC Group

康桥资本是亚洲最大和最活跃的医疗健康行业的私募股权基金之一，专注于生物医药、医疗技术和医疗服务三个核心领域的平台建设和收购机遇。康桥资本赋能医疗健康行业领军企业的变革，以实现长期可持续增长，解决尚未满足的医疗需求，不断提高中国和亚洲其他地区的全民医疗健康水平及生活质量。康桥资本成立于

2014 年，在新加坡、上海、北京、香港和纽约拥有强大的投资、医疗和投资组合管理的专业团队。

关于国新国同（GT Fund）

国新国同基金区域性、产业型子基金浙江制造基金（以下统称“国新国同”），是 2017 年在中国杭州注册成立的私募股权基金，总规模为 100 亿元人民币（约 14 亿美元）。国新国同致力于为该区域的产业合作伙伴提供资金和专业支持，坚持市场化、专业化、国际化的原则，积极投资医药医疗、先进制造、清洁能源等领域的跨境投资项目。国新国同的投资组合力求为联合投资者和有限合伙人提供卓越的风险调整回报。国新国同基金是 2016 年成立的私募股权基金，基金总规模为 1500 亿元人民币（约 211 亿美元）。

关于 RTW Investments, LP

RTW Investments, LP（以下统称“RTW”）是一家总部位于纽约的全球性全生命周期投资公司，专注于发掘生物制药和医疗技术的变革性和颠覆性创新。作为行业和学术界的领先合作伙伴，RTW 将深厚的科学专业知识与以解决方案为导向的投资方法相结合，助力新兴医疗疗法以及研发这些疗法的公司和学者。